Work

In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018

Year: 2021

Type: article

Abstract: OBJECTIVES: This study examined the in vitro activity of iclaprim and comparators against 40 Listeria monocytogenes clinical isolates mostly (95%) from patients with bloodstream infection (BSI) from the USA, Australia/New Zealand, Latin America and Europe collected between 2012-2018. METHODS: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI criteria. RESULTS: values for iclaprim were 4-fold lower than trimethoprim, the only FDA-approved dihydrofolate reductase inhibitor, against all L. monocytogenes. CONCLUSION: Iclaprim demonstrated lower MIC values than trimethoprim against a collection (2012-2018) of L. monocytogenes clinical isolates mostly from patients with BSI from the USA, Australia/New Zealand, Latin America and Europe.

Source: Journal of Global Antimicrobial Resistance

DOI: 10.1016/j.jgar.2021.02.015

Authors: David B. Huang, Leonard R. Duncan, Yahse K. Edah, Paul R. Rhomberg, Robert K. Flamm, Michael D. Huband

Institutions: Motif BioSciences (United States), Rutgers New Jersey Medical School, JMI Laboratories

Language: English

Topic: Listeria monocytogenes in Food Safety

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,920